Literature DB >> 9469503

Correcting impotence in the male dialysis patient: experience with testosterone replacement and vacuum tumescence therapy.

I G Lawrence1, D E Price, T A Howlett, K P Harris, J Feehally, J Walls.   

Abstract

Sexual dysfunction remains a common and often distressing problem in the male dialysis population. Traditionally its management has consisted of correction of anemia, optimization of dialysis, removal of implicated medication, and finally depot injections of a testosterone ester. At a dedicated renal impotence clinic, we studied the effectiveness of testosterone replacement in men with biochemically proven hypogonadism and then vacuum tumescence therapy in those with continued erectile dysfunction. Depot testosterone was given to 27 patients (aged 52.4+/-2.5 years; duration of dialysis, 2.00+/-0.40 years; and duration of sexual dysfunction, 2.92+/-0.49 years): sexual function was fully restored in only three (11.1%), and two gradually lost the response over 18 months. Nineteen patients (70.3%) had partial responses, varying from an increased sense of well-being alone to restored sexual function apart from an impairment of the duration of penile erection. Five patients (18.5%) had no response, and testosterone was contraindicated in another four. Four of the treated patients (14.8%) reported fluid retention. Vacuum tumescence devices were then offered to 32 patients who remained impotent but declined by six. Twenty-six patients (aged 49.6+/-2.2 years; duration of dialysis, 2.50+/-0.58 years; and duration of sexual dysfunction, 3.26+/-0.56 years) used the devices, with 19 (73.1%) having full correction of their erectile dysfunction; six also continued with depot testosterone to maintain their libido. Penile discomfort was described by five patients (19.2%) whose potency was not restored. A further five predialysis patients have used the devices, and all had correction of their erectile dysfunction. The correction of biochemical hypogonadism in the male dialysis population with testosterone rarely restores sexual function to normal, whereas vacuum tumescence therapy corrects penile erection dysfunction in most patients.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9469503     DOI: 10.1053/ajkd.1998.v31.pm9469503

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  9 in total

1.  Sexual Inactivity among hemodialysis patients: the patients' perspective.

Authors:  Fredric O Finkelstein; Susan H Finkelstein
Journal:  Clin J Am Soc Nephrol       Date:  2013-12-19       Impact factor: 8.237

Review 2.  Erectile dysfunction in hemodialysis: A systematic review.

Authors:  Ahmed El-Assmy
Journal:  World J Nephrol       Date:  2012-12-06

Review 3.  Gonadal dysfunction in chronic kidney disease.

Authors:  Biff F Palmer; Deborah J Clegg
Journal:  Rev Endocr Metab Disord       Date:  2017-03       Impact factor: 6.514

Review 4.  Chronic kidney disease and erectile dysfunction.

Authors:  Etsu Suzuki; Hiroaki Nishimatsu; Shigeyoshi Oba; Masao Takahashi; Yukio Homma
Journal:  World J Nephrol       Date:  2014-11-06

5.  Serum testosterone levels and mortality in men with CKD stages 3-4.

Authors:  Kiranpreet K Khurana; Sankar D Navaneethan; Susana Arrigain; Jesse D Schold; Joseph V Nally; Daniel A Shoskes
Journal:  Am J Kidney Dis       Date:  2014-04-13       Impact factor: 8.860

Review 6.  Hypogonadism and testosterone replacement therapy in end-stage renal disease (ESRD) and transplant patients.

Authors:  Grace Snyder; Daniel A Shoskes
Journal:  Transl Androl Urol       Date:  2016-12

7.  A case series of the safety and efficacy of testosterone replacement therapy in renal failure and kidney transplant patients.

Authors:  Ahmad Majzoub; Daniel A Shoskes
Journal:  Transl Androl Urol       Date:  2016-12

Review 8.  Male Sexual Dysfunction and Chronic Kidney Disease.

Authors:  Matthew M Edey
Journal:  Front Med (Lausanne)       Date:  2017-03-22

9.  Androgens and Anemia: Current Trends and Future Prospects.

Authors:  Ahmed Al-Sharefi; Azmi Mohammed; Altayeb Abdalaziz; Channa N Jayasena
Journal:  Front Endocrinol (Lausanne)       Date:  2019-11-14       Impact factor: 5.555

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.